Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) has announced plans to initiate a Health Canada-authorized Phase 3 clinical trial in 2027 evaluating MDMA-assisted therapy for post-traumatic stress disorder (PTSD). The trial is intended to enroll up to 100 participants across multiple Canadian sites, focusing on veterans and current or former frontline workers, including military personnel, police, paramedics, firefighters, and healthcare workers. Participants will receive Optimi's synthetic MDMA HCl during two supervised sessions combining MDMA and psychotherapy, with the primary efficacy endpoint measuring changes in PTSD severity using the Clinician-Administered PTSD Scale.
This planned Phase 3 trial follows Optimi's recently announced Phase 2 trial of natural psilocybin for major depressive disorder and is part of the company's goal of pursuing registration for both products. Optimi noted that the safety and efficacy of MDMA-assisted therapy for PTSD remain under investigation and none of its MDMA drug products have received market authorization from Health Canada. The company said clinics in Australia have been prescribing MDMA manufactured by Optimi since October 2024.
The announcement signals a significant step forward in the clinical development of psychedelic-assisted therapies for mental health conditions, particularly for PTSD, which affects many veterans and frontline workers. If successful, this trial could lead to regulatory approval and expanded access to MDMA-assisted therapy in Canada, offering a new treatment option for patients who have not responded to traditional therapies. The focus on frontline workers highlights the urgent need for effective mental health interventions in high-stress professions.
Optimi Health Corp. is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, Optimi produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia, Canada. Optimi supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally, with products currently prescribed to patients in Australia under the country's Authorized Prescriber Scheme and accessible in Canada through the Special Access Program. For more information, visit https://www.optimi.net/.
The trial's design, combining MDMA with psychotherapy, reflects a growing body of research suggesting that psychedelic compounds can enhance therapeutic outcomes when used in controlled clinical settings. However, the company cautions that MDMA-assisted therapy for PTSD is still under investigation and has not been approved by Health Canada. This trial, if successful, could pave the way for regulatory submission and eventual market authorization, potentially transforming treatment paradigms for PTSD. For full press release, visit https://ibn.fm/tr50L.
For the healthcare industry, this development underscores the increasing interest in psychedelic medicine as a viable treatment avenue for mental health disorders. It also highlights the role of Canadian companies in advancing research and manufacturing capabilities in this emerging field. Patients and healthcare providers should stay informed about the progress of this trial and any future regulatory decisions that may impact access to MDMA-assisted therapy.
